Catatonic neuroleptic syndrome under aripiprazole and paroxetine;Katatones neuroleptisches syndrom unter aripiprazol und paroxetin

Psychopharmakotherapie

Volumn 14, Issue 5, 2007, Pages 215-217

  Holtschmidt Täschner, Bettina ^a   Stübner, Susanne ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; PAROXETINE;

ARTICLE; EXTRAPYRAMIDAL SYNDROME; HUMAN; NEUROLEPTIC MALIGNANT SYNDROME;

EID: 35349030801     PISSN: 09446877     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Berry RV, Sheldon HK, Kline A. An unusual complication following the use of trilafon in children. U.S Armed Forces Med J 1958;9:745-9.
2. Brahm NC, McElwain DL, Brown RC. Potential aripiprazole-mediated extrapyramidal symptoms in an adult with developmental disabilities. Am J Health Syst Pharm 2007;64:827-9.
3. 2 dopamine receptors. J Pharmacol Exp Ther 2002;302:381-9.
4. Carlsson A, Waters N, Waters S, Carlsson ML. Network interactions in schizophrenia-therapeutic implications. Brain Res Rev 2000;31:342-9.
5. Caroff SN. The neuroleptic malignant syndrome. J Clin Psychiatry 1980;41:79-83.
6. Ciraulo DA, Shader RI, Greenblatt J, Creelman W (eds.). Drug Interactions in Psychiatry. 3. ed. Philadelphia: Lippincott Williams & Wilkins, 2006.
7. Cozza KL, Armstrong SC, Oesterheld JR. Drug Interaction Principles for Medical Practice. 2. ed. London, England: American Psychiatric Publishing Inc. Washington DC, 2003.
8. Cohen ST, Rulf D, Pies R. Extrapyramidal side effects associated with aripiprazole coprescription in 2 patients. J Clin Psychiatry 2005;66:135-6.
9. Ekbom K, Lindholm H, Ljungberg L. New dystonic syndrome associated with butyrophenone therapy. Z Neurol 1972;202:94-103.
10. Gaertner HJ, Hörner W, Bartels M. Katatonieforme Symptome als Nebenwirkung neuroleptischer Behandlung. Nervenarzt 1983;54:250-4.
11. Gelenberg AJ, Mandel MR. Catatonic reactions to high-potency neuroleptic drugs. Arch Gen Psychiatry 1977;34:947-50.
12. Hung GC, Chen YY. Extrapyramidal side effects associated with aripiprazole administration in a schizophrenic patient. Pharmacopsychiatry 2007;40:83-4.
13. Inoue T, Domac M, Yamada K, Furukawa T. Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4- dihydro-2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J Pharmacol Exp Ther 1996;277:137-43.
14. Lane R. SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment. J Psychopharmacol 1998;12:192-214.
15. Marder SR, McQuade RD, Stock E, Kaplita S, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophrenia Res 2003;61:123-36.
16. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics: Part 1. "Goldilocks" actions at dopamine receptors. J Clin Psychiatry 2001;62:824-41.
17. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics: Part 2. Illustrating their mechanism of action. J Clin Psychiatry 2001;62:923-4.
18. Stubner S, Padberg F, Grohmann R, Hampel H, et al. Pisa syndrome (pleurothotonus): report of a multicenter drug safety surveillance project. J Clin Psychiatry 2000;61:569-74.
19. Suzuki T, Koizumi J, Moroji T, Sakuma K, et al. Clinical characteristics of the Pisa syndrome. Acta Psychiatr Scand 1990;82:454-7.